Portal de investigación
ESTUDIO DE COHORTES, PROSPECTIVO DE DATOS DE LA VIDA REAL EN EL TRATAMIENTO DEL CÁNCER COLORRECTAL METASTÁSICO: PERSPECTIVA CLÍNICA Y DEL PACIENTE. (PROMETCO).
Datos básicos
- Protocolo:
- SAM-ONC-2018-01
- EUDRACT:
- NCT:
- Centro:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Año de incio:
- 2019
- Año de finalización:
- 2024
Documentos
- No hay documentos
Participantes
Financiadores - Promotores
Resultados del Ensayo Clínico
A microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant therapy in stage II and III colorectal cancer.
Okuno, Keisuke; (...); Goel, Ajay
Letter. 10.1186/s12943-022-01699-2. 2023
Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP).
Riechelmann RP; (...); Sobrero A
Article. 10.1016/j.clcc.2019.05.003. 2019
Cancer worry at higher-risk sample of hereditary cancer in Spain.
Costa-Requena G, Richart-Aznar P, Segura-Huerta Á
Article. 10.1097/CEJ.0000000000000862. 2024
Clinical Impact of Circulating Tumor RAS and BRAF Mutation Dynamics in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy Plus Anti-Epidermal Growth Factor Receptor Therapy
Maurel, J; (...); Montagut, C
Article. 10.1200/PO.18.00289. 2019
Comparison of psychological distress for breast, ovarian and colorectal cancer predisposition in a Spanish sample at high risk of hereditary cancer.
Costa-Requena, Gema; (...); Segura-Huerta, Angel
Article. 10.1097/CEJ.0000000000000734. 2022
Concordance of baseline RAS mutational status (ms) between tissue and cell-free DNA (cfDNA) and association with overall response rate (ORR) in first-line (1L) metastatic colorectal cancer (mCRC) patients (pts): PERSEIDA study (cohort 2) (NCT02792478)
Valladares-Ayerbes, M; (...); Vila, AL
Meeting Abstract. 10.1016/j.annonc.2021.08.976. 2021
Correction to: Recommendations for follow-up of colorectal cancer survivors.
Vera R; (...); Fernández-Cebrián JM
Article. 10.1007/s12094-019-02088-w. 2019
Correction: Update on the management of elderly patients with colorectal cancer.
Soler-González G; (...); Gironés-Sarrió R
Correction. 10.1007/s12094-023-03351-x. 2024
Correlation of RECIST, Computed Tomography Morphological Response, and Pathological Regression in Hepatic Metastasis Secondary to Colorectal Cancer: The AVAMET Study
Vera, R; (...); Viudez, A
Article. 10.3390/cancers12082259. 2020
Characterizing diversity in the immune profile by a transcriptomic customized gene signature to potentially personalize treatment in advanced gastric cancer patients
Cabeza-Segura, M; (...); Fleitas, T
Meeting Abstract. 10.1016/j.annonc.2021.08.1541. 2021
Development of a predictive model of venous thromboembolism recurrence in anticoagulated cancer patients using machine learning.
Munoz, Andres J.; (...); Hernandez-Presa, Miguel Angel
Article. 10.1016/j.thromres.2023.06.015. 2023
Development, Implementation and Assessment of Molecular Diagnostics by Next Generation Sequencing in Personalized Treatment of Cancer: Experience of a Public Reference Healthcare Hospital.
Simarro J; (...); Palanca S
Article. 10.3390/cancers11081196. 2019
Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?
Contreras-Toledo, Debora; (...); Carmona-Bayonas, Alberto
Article. 10.1038/s41416-023-02563-w. 2024
European Association of Urology (EAU) Testicular Cancer Guidelines Panel: A new prognostic factor risk group classification for patients with clinical stage 1 seminoma in active surveillance.
Boormans, Joost; (...); Laguna, Pilar
Meeting Abstract. 2023
Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study.
Valladares-Ayerbes M; (...); Lloansí Vila A
Article. 10.3390/cancers14246075. 2022
First-line chemotherapy with or without targeted therapies in metastatic colorectal cancer: The GEMCAD 14-01 prospective cohort
Oliveres, H.; (...); Maurel, J.
Meeting Abstract. 10.1016/j.annonc.2023.09.1796. 2023
Human chorionic gonadotropin-positive seminoma patients: A registry compiled by the global germ cell tumor collaborative group (G3)
Seidel, C; (...); Bokemeyer, C
Article. 10.1016/j.ejca.2020.03.022. 2020
Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study.
Rodríguez-Lescure Á; (...); de la Haba-Rodriguez J
Article. 10.1007/s12094-024-03411-w. 2024
Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma
Cabeza-Segura, Manuel; (...); Fleitas, Tania
Article. 10.1038/s41416-022-02005-z. 2022
M2 macrophages could promote an immunosuppressive phenotype in a prospective cohort of advanced gastric cancer patients
Cabeza, M; (...); Fleitas, T
Meeting Abstract. 10.1016/j.annonc.2020.08.1986. 2020
Maintenance of angiogenesis inhibition with aflibercept after progression to bevacizumab in metastatic colorectal cancer: real life study in the Valencian community.
Raga, Mireia Gil; (...); Hernandez, Isabel Busquier
Article. 10.1007/s12094-022-03047-8. 2023
Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease.
Aparicio J; (...); Fernandez-Montes A
Review. 10.3390/jcm9123889. 2020
Outcome of men with relapses after adjuvant BEP for clinical stage I nonseminoma.
Fischer, Stefanie Christine; (...); Gillessen, Silke
Meeting Abstract. 10.1200/JCO.2019.37.7_suppl.510. 2019
Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma.
Fischer S; (...); Global Germ-Cell Cancer Group
Article. 10.1200/JCO.19.01876. 2020
Patterns of relapse and treatment outcome after active surveillance or adjuvant carboplatin for stage I seminoma: a retrospective study of the Spanish Germ Cell Cancer Group.
Aparicio, J.; (...); Germa, J. R.
Article. 10.1007/s12094-020-02393-9. 2021
Predicting major bleeding events in anticoagulated cancer patients with venous thromboembolism using real-world data and machine learning.
Martin, Andres J. Munoz; (...); Hernandez-Presa, Miguel Angel
Meeting Abstract. 2022
Predicting recurrence of venous thromboembolism in anticoagulated cancer patients using real-world data and machine learning.
Martin, Andres J. Munoz; (...); Hernandez-Presa, Miguel Angel
Meeting Abstract. 2022
Prevalence and Clinicopathological Characteristics of Moderate and High-Penetrance Genes in Non-BRCA1/2 Breast Cancer High-Risk Spanish Families
Fonfria, M; (...); Martinez-Duenas, E
Article. 10.3390/jpm11060548. 2021
Prognosis of anaemia in disseminated testicular germ cell tumours. On behalf of the Spanish Germ Cell Cancer Group (SGCCG)
Torralba, EG; (...); Billalabeitia, EG
Meeting Abstract. 2019
Prognostic Factor Risk Groups for Clinical Stage I Seminoma: An Individual Patient Data Analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines Office.
Boormans, Joost L; (...); Laguna, M Pilar
Article. 10.1016/j.euo.2023.10.014. 2023
Prognostic factors in metastatic seminomatous germ cell tumours and elevated human chorionic gonadotrophin (HCG): A study of the G3
Seidel, C; (...); Bokemeyer, C
Meeting Abstract. 2019
Prognostic impact of LDH and HCG levels in marker-positive seminomas
Seidel, Christoph Alexander; (...); Bokemeyer, Carsten
Meeting Abstract. 2020
Psychiatric symptoms in a Spanish sample with hereditary cancer risk.
Costa-Requena G; (...); Segura-Huerta Á
Article. 10.1007/s12687-022-00580-5. 2022
Ramucirumab effectiveness in patients with advanced gastric cancer or gastro-esophageal junction adenocarcinoma in clinical practice in Spain: Sub-analysis of RAMIS study
Longo, F; (...); Sedano, MO
Meeting Abstract. 10.1016/j.annonc.2020.04.125. 2020
Randomized phase II clinical trial to evaluate the efficacy of second line FOLFIRI-panitumumab in patients with RAS wild -type metastatic colorectal cancer who have received FOLFOXpanitumumab in first -line (BEYOND)
Aparicio, J; (...); Maurel, J
Meeting Abstract. 10.1093/annonc/mdz155.190. 2019
Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01)
Aparicio, Jorge; (...); Maurel, Joan
Article. 10.1007/s12094-022-02868-x. 2022
Randomized phase II trial of second-line FOLFIRI-panitumumab vs FOLFIRI alone in Ras wild type (wt) metastatic colorectal cancer (mCRC) patients beyond progression to first-line FOLFOX-panitumumab: BEYOND study (GEMCAD 17-01)
Aparicio, J; (...); Maurel, J
Meeting Abstract. 10.1016/j.annonc.2021.08.937. 2021
Real-life use of ramucirumab in gastric cancer in Spain: the RAMIS study.
Longo F; (...); Díaz-Cerezo S
Article. 10.2217/fon-2020-1216. 2021
Recent treatment advances in clinical stage i nonseminomatous germ cell tumors.
Letter. 10.1016/j.acuro.2020.08.014. 2021
Recommendations for follow-up of colorectal cancer survivors
Vera, R; (...); Fernandez-Cebrian, JM
Article. 10.1007/s12094-019-02059-1. 2019
Retrospective real-world data study using natural language processing to describe treatment sequence and clinicopathological patterns in patients with metastatic colorectal cancer in five Spanish institutions
Vera Garcia, R.; (...); Mondejar Solis, R.
Meeting Abstract. 10.1016/j.annonc.2023.04.343. 2023
SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019).
Martín-Richard M; (...); Sastre J
Article. 10.1007/s12094-019-02259-9. 2020
SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021).
Fernandez-Montes, Ana; (...); Martin-Richard, Marta
Article. 10.1007/s12094-022-02801-2. 2022
SEOM-GEMCAD-TTD clinical guidelines for the systemic treatment of metastatic colorectal cancer (2022).
Fernandez Montes, Ana; (...); Aparicio, Jorge
Article. 10.1007/s12094-023-03199-1. 2023
Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study.
Valladares-Ayerbes M; (...); Lloansí Vila A
Article. 10.1007/s12094-024-03487-4. 2024
The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3).
Seidel C; (...); Oing C
Article. 10.1007/s00345-021-03635-3. 2021
Treatment and Outcome of Patients with Stage IS Testicular Cancer: A Retrospective Study from the Spanish Germ Cell Cancer Group.
Aparicio J; (...); Terrasa J
Article. 10.1097/JU.0000000000000366. 2019
Update on the management of elderly patients with colorectal cancer.
Soler-Gonzalez, Gemma; (...); Girones-Sarrio, Regina
Article. 10.1007/s12094-023-03243-0. 2023
Venous thromboembolism recurrence during anticoagulant treatment in gastrointestinal cancer patients
Munoz Martin, A.; (...); Angel Hernandez-Presa, M.
Meeting Abstract. 2022